Divaka Perera, ACC 2023: REVIVED-BCIS2 trial - Myocardial viability in left ventricular dysfunction

The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction.  In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy's and St Thomas' NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely have on clinical practice.

The abstract entitled ‘Effect Of Myocardial Viability, Percutaneous Coronary Intervention And Functional Recovery On Clinical Outcomes In The REVIVED-BCIS2 Randomized Trial’ (Abstract number 403-10) was presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023. 

Questions:

What were the aims and methodology of the REVIVED-BCIS2 viability trial? (0:17)
What were the findings of the trial? (3:23)
What is the potential clinical significance of these findings? (5:40)

Disclosures: Divaka Perera has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Subtitles and transcript are autogenerated